Abstract
A new series of heteroleptic copper(II) complexes of the type [Cu(L1−3)(diimine)](ClO4) (1–6) have been synthesized using three pyridazine-based ligands (3-chloro-6-(salicylidenehydrazinyl)pyridazine (HL1), 3-chloro-6-(4-diethylaminosalicylidenehydrazinyl)pyridazine (HL2) and 3-chloro-6-(5-bromosalicylidenehydrazinyl)pyridazine (HL3), and diimine (2,2′-bipyridine (bpy) or 1,10-phenanthroline (phen)) as co-ligands. The ligands and their copper(II) complexes have been characterized by elemental analyses and spectroscopic methods. The copper(II) complexes display ligand-field band in the region 641–661 nm suggesting square pyramidal geometry. The optimized structures of the complexes and their molecular orbital calculations obtained by the density functional theory (DFT) also showed five coordinated distorted square pyramidal geometry around the copper(II) ion. The cyclic voltammetric analyses of copper(II) complexes exhibit one-electron irreversible reduction wave (Epc = −0.596 to −0.641 V) in the cathodic potential region. Anti-proliferative activity of the complexes against breast cancer MDA-MB-231 cell line was evaluated by MTT cell proliferation assay, and the clonogenic assay revealed improved cytotoxicity for the complexes with potency higher than the standard drug cisplatin. Since the complexes 3 and 4 with diethylamino substituent displayed higher anti-proliferative activity than the other complexes, these complexes were chosen for apoptosis and cell cycle analysis. The apoptosis induction was analyzed by AO/EB staining, and the flow cytometry showed the inhibition of cell growth at the S-phase of the cell cycle. Additionally, the interaction of copper(II) complexes with FGFR kinase receptor have been studied by in silico molecular docking studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.